Compare Capital One Financial Corp. (COF) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capital One Financial Corp. vs GeneDx Holdings Corp — how do they compare? Capital One Financial Corp. trades at $209.42 (market cap $126.46B), while GeneDx Holdings Corp trades at $62.75 (market cap $1.85B). The key difference: Capital One Financial Corp. is far larger — about 68.4× GeneDx Holdings Corp's market cap, and Capital One Financial Corp. pays a 1.56% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| COF | WGS | |
|---|---|---|
Market Cap | $126.46B | $1.85B |
Sector | Financials | Technology |
52-Week High | $257.94 | $167.51 |
52-Week Low | $176.10 | $34.51 |
Dividend Yield | 1.56% | — |
Enterprise Value | — | $1.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Capital One Financial (COF) trades at $203.02, up 0.74% with a bullish technical signal from moving averages. The stock shows mixed earnings performance with recent misses but strong revenue growth to $53.43B in 2025. Analyst consensus remains positive with a $252.40 price target and 62.5% buy ratings, while the Discover integration presents significant expansion opportunities amid credit risk concerns.
COF offers potential upside from current levels with Wall Street optimism around the Discover acquisition, though investors face headwinds from rising delinquencies and margin compression. The stock's valuation at 62.44 P/E appears elevated relative to modest ROE of 3.34%, requiring careful monitoring of integration execution and credit quality trends.
GeneDx Holdings (WGS) trades at $63.85, down 2.73% amid multiple securities class action lawsuits alleging misleading acquisition performance disclosures. The stock shows bearish technical signals with support at $60 and resistance at $65. Fundamentally, the company reported negative net income of -$21.02M for 2025 despite revenue growth to $427.54M, with profitability metrics deteriorating significantly in 2026 projections.
Despite 91% analyst buy ratings and a $75.40 consensus target, substantial legal risks and negative earnings momentum create significant headwinds. The stock faces near-term pressure from litigation while long-term viability depends on reversing negative margin trends and resolving acquisition-related impairment issues that triggered the 49% stock decline cited in lawsuits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
